Vistagen Therapeutics (VTGN) Price to Book (2012 - 2026)

Vistagen Therapeutics has disclosed Price to Book across 15 years of filings, most recently posting 0.42 for Q2 2026.

• In Q2 2026, Price to Book fell 61.43% year-over-year to 0.42; the TTM figure through Jun 2026 stood at 0.42 (down 61.43% YoY), while the FY2026 annual figure was 0.66, down 36.42% from the prior year.
• Price to Book came in at 0.42 for Q2 2026 at Vistagen Therapeutics, down from 0.66 in the prior quarter.
• In the past five years, Price to Book ranged from a high of 3.96 in Q1 2022 to a low of 0.04 in Q2 2023.
• Average Price to Book over 5 years is 1.36, with a median of 1.04 recorded in 2025.
• Year-over-year, Price to Book sank 98.93% in 2023 and surged 2016.49% in 2024.
• Over 5 years, Price to Book stood at 1.0 in 2022, then rose by 12.5% to 1.13 in 2023, then slipped by 6.85% to 1.05 in 2024, then tumbled by 51.07% to 0.51 in 2025, then declined by 18.81% to 0.42 in 2026.
• Per Business Quant data, the three most recent Price to Book figures were 0.42 in Q2 2026, 0.66 in Q1 2026, and 0.51 in Q4 2025.